- AFM13: Encouraging data supports initiation of
monotherapy registration-directed study in first half of 2019;
Combination study with cord blood-derived natural killer cells
planned to initiate at MD Anderson; Clinical data updates from
monotherapy study and combination study with Keytruda®
(pembrolizumab) expected in 2019 -
- AFM24: IND submission planned for mid-2019;
Plans to initiate first-in-human study in second half of 2019 -
- AFM11: Submitted all documents as requested by
FDA in an effort to resume the AFM11 clinical program in ALL -
Heidelberg, Germany, March 27, 2019 - Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
committed to giving patients back their innate ability to fight
cancer, today provided an update on recent operational progress and
reported financial results for the year ended December 31,
2018.
“2018 was a year in which Affimed made
substantial progress. We achieved tremendous clinical and corporate
milestones that further demonstrated our innate immunity expertise
and the potential for therapeutics based on our novel
CD16A-targeting innate cell engager approach to treat cancer,” said
Dr. Adi Hoess, Affimed’s CEO. “With our current financial
resources, including funds received from Genentech under our
collaboration, we believe we are well-positioned to achieve
additional milestones in 2019 and beyond, including advancing our
lead development candidate, AFM13, into a market
registration-directed study and entering the clinic with AFM24, our
second innate cell engager and a potential treatment for multiple
solid tumor malignancies.”
Anticipated 2019 Milestones
- Affimed plans to initiate in the first half of 2019 a Phase 2
registration-directed study of AFM13 as monotherapy in relapsed or
refractory patients with peripheral T cell lymphoma (PTCL) and
transformed mycosis fungoides (TMF), a subset of cutaneous T cell
lymphoma (CTCL).
- Affimed plans to report updated data from the combination study
of AFM13 with Merck’s Keytruda® (pembrolizumab) in patients with
relapsed or refractory Hodgkin lymphoma (HL), and expects
additional data from Columbia University’s study investigating
AFM13 monotherapy in patients with relapsed or refractory
CD30-positive lymphoma with cutaneous lesions in the first half of
2019.
- A study of cord blood-derived allogeneic natural killer (NK)
cells in combination with AFM13 is planned to be initiated by
Affimed’s collaboration partner The University of Texas MD Anderson
Cancer Center (MDACC) in the first half of 2019.
- Affimed plans to report updated data of AFM24 at the American
Association for Cancer Research (AACR) Annual Meeting 2019, March
29 - April 3, 2019, and anticipates completing investigational new
drug (IND)-enabling studies of AFM24 by mid-year 2019 to support
the initiation of the first-in-human study of AFM24 in the second
half of 2019.
Key Pipeline Updates
CD16A innate cell engager programs
AFM13 (CD30/CD16A)
- Data from an investigator-sponsored translational Phase 1b/2a
study of AFM13 in patients with relapsed or refractory
CD30-positive lymphoma with cutaneous manifestation led by Columbia
University were presented at the 60th American Society of
Hematology (ASH) Annual Meeting and Exposition in December 2018.
The data confirmed single-agent activity of AFM13 in CD30-positive
lymphoma patients. In addition, an analysis of biomarker
correlatives showed a temporary decrease in circulating NK cells
during therapy, with post therapy recovery. Tumor biopsies showed
increased infiltration of CD56+ NK cells in responders compared to
non-responders.
- Affimed provided an update on its Phase 1b trial of AFM13 in
combination with pembrolizumab in patients with HL. Data from 24
patients showed that the combination of AFM13 and pembrolizumab
could be safely administered and achieved objective response and
complete response (CR) rates that compare favorably to the
historical data of pembrolizumab in a similar patient population,
with the CR rate approximately double that of pembrolizumab. The
data was presented at the ASH Annual Meeting 2018.
- An oral presentation by MDACC at the ASH Annual Meeting 2018
described the successful development of a novel premixed product of
expanded allogeneic cord-blood derived NK cells preloaded with
AFM13 to redirect the specificity of NK cells against CD30-positive
malignancies in preclinical models, as well as in vivo data
confirming the antitumor activity of these AFM13-NK cells.
- Based on preliminary feedback from the U.S. Food and Drug
Administration (FDA) and on data presented at the ASH Annual
Meeting 2018, Affimed announced plans at the Company’s Research
& Development Day in December to pursue a registrational
pathway for AFM13 monotherapy in relapsed or refractory patients
with PTCL and TMF with potential for accelerated approval. The
broader clinical development strategy for AFM13 includes
potentially expanding into other CD30-positive lymphoma indications
and additional treatment lines with significant unmet need. In
collaboration with strategic partners, Affimed plans to investigate
AFM13 in combination with other immunotherapy agents, such as an
anti-PD-1/PD-L1 antibody agent and with adoptive NK cell
transfer.
- Together with its collaboration partners from Washington
University School of Medicine, Saint Louis, MO, Affimed will
present data at the AACR Annual Meeting 2019, aimed at describing
NK cell functional responses to tumor cells triggered by
AFM13.
AFM24 (EGFR/CD16A)
- Innate cell engagers developed from Affimed’s ROCK® (Redirected
Optimized Cell Killing) platform enable targeting of clinically
validated tumor antigens, such as EGFR, for which current therapies
have shown limited efficacy due to resistance and/or dose-limiting
toxicities. AFM24, designed to treat patients with a variety of
EGFR-expressing solid tumors, has the potential for broader
efficacy through higher potency at both high and low EGFR
expression levels and in KRAS mutant tumors, as well as a more
favorable safety profile as compared to current therapeutic
anti-EGFR monoclonal antibodies. Affimed will present data at the
AACR Annual Meeting 2019 that highlights the differentiating
features of AFM24 versus standard of care anti-EGFR therapies, such
as cetuximab, including tumor cell killing independent of RAS
mutational status, induced tumor lysis through antibody-dependent
cellular cytotoxicity (ADCC) and antibody-dependent cellular
phagocytosis (ADCP), as well as toxicology studies demonstrating a
favorable safety profile.
T cell engager programs
AFM11 (CD19/CD3)
- Preliminary data on the clinical activity and safety of AFM11
from a Phase 1 study of AFM11 in relapsed/refractory acute
lymphoblastic leukemia (ALL), including several patients with
complete remissions, were presented at the ASH Annual Meeting
2018.
- Affimed recently submitted a complete response document to the
FDA that summarizes the clinical data from the two AFM11 Phase 1
studies with a request that the clinical hold be lifted so that
clinical development of AFM11 may proceed in patients with
ALL.
2018 Corporate Updates
- In February, Affimed raised approximately $24.5 million (€19.7
million) in net proceeds from an underwritten public offering.
- In March, Leila Alland, M.D. joined Affimed as Chief Medical
Officer. Dr. Alland brings more than 20 years of oncology
experience, having held leadership roles in drug development at
Tarveda Therapeutics, AstraZeneca, Bristol-Myers Squibb and
Novartis.
- In May, Affimed introduced its ROCK® (Redirected Optimized Cell
Killing) platform. The Company's proprietary, unique and
fit-for-purpose ROCK® platform enables the generation of
first-in-class, tetravalent, multi-specific immune cell engagers.
Based on its modularity, ROCK® allows for antibody engineering of
highly customizable innate and T cell engagers to generate clinical
candidates tailored to multiple disease indications and settings,
including generation of molecules against validated oncology
targets, to address the limitations of existing treatments.
- In August, Affimed entered into a research collaboration and
license agreement with Genentech, a member of the Roche Group, to
develop and commercialize novel NK cell engager-based
immunotherapeutics based on Affimed's ROCK® platform to treat
multiple cancers. Affimed received $96 million in upfront and
committed funding, and may be eligible to receive up to an
additional $5 billion including payments on achievement of certain
development, regulatory and commercial milestones, plus royalties
on sales. In March 2019, Affimed announced that it will receive a
payment in an undisclosed amount triggered by the achievement of a
preclinical milestone under its collaboration with Genentech.
2018 Financial Highlights
Cash, cash equivalents and current financial
assets totaled €108.8 million as of December 31, 2018 compared to
€39.8 million as of December 31, 2017. Affimed anticipates that its
cash, cash equivalents and current financial assets as of December
31, 2018 will enable the Company to fund its operations, including
clinical development and early development activities, into 2021
assuming all of the Company’s programs advance as currently
contemplated.
Net cash from operating activities was €49.4
million for the twelve months ended December 31, 2018 compared to
net cash used in operating activities of €25.5 million for the
twelve months ended December 31, 2017. The amount in 2018 includes
an initial upfront payment and committed funding of €83.2 million
from the Genentech collaboration.
Affimed recognized €21.8 million as revenue from
the Genentech collaboration in 2018 and €61.4 million under
contract liabilities, which will be recognized as revenue in
subsequent periods. Total revenue was €23.7 million for the year
ended December 31, 2018 compared to €2.0 million for the year ended
December 31, 2017.
Research and development (R&D) expenses were
€35.1 million for the year ended December 31, 2018 compared to
€21.5 million for the year ended December 31, 2017. The increase
was related to higher expenses for AFM13 and AFM11 clinical
development activities, as well as early stage development and
discovery activities.
General and administrative (G&A) expenses
were €9.6 million for the year ended December 31, 2018, compared to
€8.0 million for the year ended December 31, 2017. This increase
was primarily related to higher legal and consulting expenses.
Net loss was €19.5 million, or €0.32 per common
share, for the year ended December 31, 2018, compared to a net loss
of €30.2 million, or €0.69 per common share, for the year ended
December 31, 2017. The decrease in net loss was primarily related
to significantly increased revenue, partially offset by higher
spending on R&D and G&A expenses.
Additional information regarding these results
is included in the notes to the consolidated financial statements
as of December 31, 2018 and “Item 5. Operating and Financial Review
and Prospects,” which will be included in Affimed’s Annual Report
on Form 20-F as filed with the U.S. Securities and Exchange
Commission (SEC).
Note on IFRS Reporting
StandardsAffimed prepares and reports the consolidated
financial statements and financial information in accordance with
International Financial Reporting Standards (IFRS) as issued by the
International Accounting Standards Board (IASB). None of the
financial statements were prepared in accordance with Generally
Accepted Accounting Principles (GAAP) in the United States. Affimed
maintains its books and records in Euro.
Conference Call and Webcast Information
Affimed will host a conference call and webcast
today, Wednesday, March 27, 2019 at 8:30 a.m. Eastern time to
discuss the Company’s financial results and recent corporate
developments. To access the call, please dial +1 (631) 510-7495 for
U.S. callers, or +44 (0) 2071 928000 for international callers, and
reference conference ID 5559486 approximately 15 minutes prior to
the call. An audio webcast of the conference call can be accessed
in the “Webcasts” section on the “Investors” page of the Affimed
website at https://www.affimed.com/investors/webcasts/. A replay of
the webcast will be available on Affimed’s website shortly after
the conclusion of the call and will be archived for 30 days
following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical stage
biopharmaceutical company committed to giving back patients back
their innate ability to fight cancer. Affimed’s fit-for-purpose
ROCK® platform allows innate immune engagers to be designed for
specific patient populations. The Company is developing single and
combination therapies to treat cancers. For more information,
please visit www.affimed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar
expressions. Forward-looking statements appear in a number of
places throughout this release and include statements regarding our
intentions, beliefs, projections, outlook, analyses and current
expectations concerning, among other things, the value of our ROCK®
platform, our ongoing and planned preclinical development and
clinical trials, our collaborations and development of our products
in combination with other therapies, the timing of and our ability
to make regulatory filings and obtain and maintain regulatory
approvals for our product candidates our intellectual property
position, our collaboration activities, our ability to develop
commercial functions, expectations regarding clinical trial data,
our results of operations, cash needs, financial condition,
liquidity, prospects, future transactions, growth and strategies,
the industry in which we operate, the trends that may affect the
industry or us and the risks uncertainties and other factors
described under the heading “Risk Factors” in Affimed’s filings
with the Securities and Exchange Commission. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
Affimed Investor
Contact:Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed Media Contact:Anca
Alexandru, Head of Communications, EU IRE-Mail:
media@affimed.com
Affimed N.V. |
|
|
|
|
|
|
|
|
Consolidated statements of comprehensive loss |
|
|
|
|
(in € thousand) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2018 |
|
|
2017 |
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
23,735 |
|
|
2,010 |
|
|
6,314 |
|
|
|
|
|
|
|
|
|
|
|
|
Other
income – net |
|
1,515 |
|
|
205 |
|
|
145 |
|
|
|
Research
and development expenses |
|
(35,148 |
) |
|
(21,489 |
) |
|
(30,180 |
) |
|
|
General and
administrative expenses |
|
(9,638 |
) |
|
(7,986 |
) |
|
(8,323 |
) |
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
(19,536 |
) |
|
(27,260 |
) |
|
(32,044 |
) |
|
|
|
|
|
|
|
|
|
|
|
Finance income / (costs) - net |
|
60 |
|
|
(2,983 |
) |
|
(230 |
) |
|
|
|
|
|
|
|
|
|
|
|
Loss before tax |
|
(19,476 |
) |
|
(30,243 |
) |
|
(32,274 |
) |
|
|
|
|
|
|
|
|
|
|
|
Income
taxes |
|
(1 |
) |
|
20 |
|
|
58 |
|
|
|
|
|
|
|
|
|
|
|
|
Loss for the period |
|
(19,477 |
) |
|
(30,223 |
) |
|
(32,216 |
) |
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income Items thatwill
not be reclassified to profit or lossEquity investments at
fair value OCI – net change in fair value |
|
(4,731 |
) |
|
0 |
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income |
|
(4,731 |
) |
|
0 |
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive loss |
|
(24,208 |
) |
|
(30,223 |
) |
|
(32,216 |
) |
|
|
|
|
|
|
|
|
|
|
|
Loss per share in € per share |
|
(0.32 |
) |
|
(0.69 |
) |
|
(0.97 |
) |
|
(undiluted = diluted) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted number of common shares outstanding |
|
60,514,407 |
|
|
43,746,073 |
|
|
33,259,505 |
|
|
Affimed
N.V. |
|
|
|
|
Consolidated
statements of financial position |
|
|
|
|
(in €
thousand) |
|
|
|
|
|
|
December 31, 2018 |
|
December 31, 2017 |
|
|
|
|
|
ASSETS |
|
|
|
|
Non-current
assets |
|
|
|
|
Intangible assets |
|
56 |
|
|
65 |
|
Leasehold improvements
and equipment |
|
1,414 |
|
|
1,113 |
|
Long term financial
assets |
|
3,825 |
|
|
0 |
|
|
|
5,295 |
|
|
1,178 |
|
|
|
|
|
|
Current
assets |
|
|
|
|
Cash and cash
equivalents |
|
94,829 |
|
|
39,837 |
|
Financial assets |
|
13,974 |
|
|
0 |
|
Trade and other
receivables |
|
1,429 |
|
|
1,102 |
|
Inventories |
|
260 |
|
|
241 |
|
Other assets |
|
387 |
|
|
800 |
|
|
|
110,879 |
|
|
41,980 |
|
|
|
|
|
|
TOTAL
ASSETS |
|
116,174 |
|
|
43,158 |
|
|
|
|
|
|
EQUITY AND
LIABILITIES |
|
|
|
|
Equity |
|
|
|
|
Issued capital |
|
624 |
|
|
468 |
|
Capital reserves |
|
239,055 |
|
|
213,778 |
|
Fair value
reserves |
|
2,594 |
|
|
0 |
|
Accumulated
deficit |
|
(202,144 |
) |
|
(182,667 |
) |
Total
equity |
|
40,129 |
|
|
31,579 |
|
|
|
|
|
|
Non current
liabilities |
|
|
|
|
Borrowings |
|
1,690 |
|
|
4,086 |
|
Contract
liabilities |
|
37,512 |
|
|
0 |
|
Total
non-current liabilities |
|
39,202 |
|
|
4,086 |
|
|
|
|
|
|
Current
liabilities |
|
|
|
|
Trade and other
payables |
|
9,425 |
|
|
4,180 |
|
Borrowings |
|
3,083 |
|
|
3,083 |
|
Contract
liabilities |
|
24,335 |
|
|
230 |
|
Total
current liabilities |
|
36,843 |
|
|
7,493 |
|
|
|
|
|
|
TOTAL EQUITY
AND LIABILITIES |
|
116,174 |
|
|
43,158 |
|
Affimed N.V. |
|
|
|
|
|
|
Consolidated statements of cash flows |
|
|
|
|
|
|
(in
€ thousand) |
|
|
|
|
|
|
|
|
2018 |
|
|
2017 |
|
|
2016 |
|
|
Cash flow from
operating activities |
|
|
|
|
|
|
|
Loss for the
period |
|
(19,477 |
) |
|
(30,223 |
) |
|
(32,216 |
) |
|
Adjustments for the
period: |
|
|
|
|
|
|
|
- Income taxes |
|
1 |
|
|
(20 |
) |
|
(58 |
) |
|
- Depreciation and
amortisation |
|
403 |
|
|
351 |
|
|
369 |
|
|
- Gain from disposal of
leasehold improvements and equipment |
|
25 |
|
|
(19 |
) |
|
0 |
|
|
- Share based
payments |
|
2,035 |
|
|
1,943 |
|
|
3,545 |
|
|
- Finance income /
(costs) - net |
|
(60 |
) |
|
2,983 |
|
|
230 |
|
|
|
|
(17,073 |
) |
|
(24,985 |
) |
|
(28,130 |
) |
|
|
|
|
|
|
|
|
|
Change in trade and
other receivables |
|
(322 |
) |
|
1,140 |
|
|
(1,311 |
) |
|
Change in
inventories |
|
(19 |
) |
|
(44 |
) |
|
31 |
|
|
Change in other
assets |
|
121 |
|
|
(399 |
) |
|
(64 |
) |
|
Change in trade, other
payables and contract liabilities |
|
66,856 |
|
|
(1,018 |
) |
|
(2,177 |
) |
|
|
|
|
|
|
|
|
|
Cash from / (used in)
operating activities |
|
49,563 |
|
|
(25,306 |
) |
|
(31,651 |
) |
|
Interest received |
|
218 |
|
|
106 |
|
|
102 |
|
|
Paid interest |
|
(342 |
) |
|
(349 |
) |
|
(578 |
) |
|
Paid income tax |
|
(1 |
) |
|
0 |
|
|
0 |
|
|
Net cash from /
(used in) operating activities |
|
49,438 |
|
|
(25,549 |
) |
|
(32,127 |
) |
|
|
|
|
|
|
|
|
|
Cash flow from
investing activities |
|
|
|
|
|
|
|
Purchase of intangible
assets |
|
(30 |
) |
|
(43 |
) |
|
(21 |
) |
|
Purchase of leasehold
improvements and equipment |
|
(691 |
) |
|
(625 |
) |
|
(238 |
) |
|
Cash received from the
sale of leasehold improvements and equipment |
|
1 |
|
|
35 |
|
|
0 |
|
|
Cash paid for
investments in convertible note and warrants |
|
0 |
|
|
(296 |
) |
|
0 |
|
|
Cash paid for
investments in financial assets |
|
(14,029 |
) |
|
(13,084 |
) |
|
(27,037 |
) |
|
Cash received from
maturity of financial assets |
|
0 |
|
|
22,063 |
|
|
18,147 |
|
|
Cash paid for
investments in long term financial assets |
|
(861 |
) |
|
0 |
|
|
0 |
|
|
|
|
|
|
|
|
|
|
Net cash from /
(used for) investing activities |
|
(15,610 |
) |
|
8,050 |
|
|
(9,149 |
) |
|
|
|
|
|
|
|
|
|
Cash flow from
financing activities |
|
|
|
|
|
|
|
Proceeds from issue of
common shares |
|
25,113 |
|
|
23,123 |
|
|
6 |
|
|
Transaction costs
related to issue of common shares |
|
(1,701 |
) |
|
(1,648 |
) |
|
0 |
|
|
Proceeds from
borrowings |
|
0 |
|
|
2,500 |
|
|
5,000 |
|
|
Transaction costs
related to borrowings |
|
0 |
|
|
(11 |
) |
|
(105 |
) |
|
Repayment of
borrowings |
|
(2,917 |
) |
|
(167 |
) |
|
(5,137 |
) |
|
Cash flow from
/ (used for) financing activities |
|
20,495 |
|
|
23,797 |
|
|
(236 |
) |
|
|
|
|
|
|
|
|
|
Exchange-rate
related changes of cash and cash equivalents |
|
669 |
|
|
(1,867 |
) |
|
179 |
|
|
Net changes to
cash and cash equivalents |
|
54,323 |
|
|
6,297 |
|
|
(41,512 |
) |
|
Cash and cash
equivalents at the beginning of the period |
|
39,837 |
|
|
35,407 |
|
|
76,740 |
|
|
Cash and cash
equivalents at the end of the period |
|
94,829 |
|
|
39,837 |
|
|
35,407 |
|
|
Affimed N.V. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated statements of changes in equity |
|
|
|
|
|
|
|
|
|
|
(in € thousand) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issued capital |
|
Capital reserves |
|
Fair value reserves |
|
Accumulated deficit |
|
Total equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2016 |
|
333 |
|
187,169 |
|
0 |
|
|
(120,228 |
) |
|
67,274 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issue of
common shares1 |
|
0 |
|
6 |
|
|
|
|
|
6 |
|
|
|
Equity-settled share based payment awards |
|
|
|
3,545 |
|
|
|
|
|
3,545 |
|
|
|
Issue of
warrant note (Perceptive loan) |
|
|
|
142 |
|
|
|
|
|
142 |
|
|
|
Loss for
the period |
|
|
|
|
|
|
|
(32,216 |
) |
|
(32,216 |
) |
|
|
Balance as of December 31, 2016 |
|
333 |
|
190,862 |
|
0 |
|
|
(152,444 |
) |
|
38,751 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2017 |
|
333 |
|
190,862 |
|
0 |
|
|
(152,444 |
) |
|
38,751 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issue of
common shares |
|
135 |
|
20,922 |
|
|
|
|
|
21,057 |
|
|
|
Equity-settled share based payment awards |
|
|
|
1,943 |
|
|
|
|
|
1,943 |
|
|
|
Issue of
warrant note (loan Silicon Valley Bank) |
|
|
|
51 |
|
|
|
|
|
51 |
|
|
|
Loss for
the period |
|
|
|
|
|
|
|
(30,223 |
) |
|
(30,223 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2017 |
|
468 |
|
213,778 |
|
0 |
|
|
(182,667 |
) |
|
31,579 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revaluation
shares Amphivena (first time adoption IFRS 9) |
|
|
|
|
|
7,325 |
|
|
|
|
7,325 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2018 |
|
468 |
|
213,778 |
|
7,325 |
|
|
(182,667 |
) |
|
38,904 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issue of
common shares |
|
156 |
|
23,171 |
|
|
|
|
|
23,327 |
|
|
|
Exercise of
share based payment awards |
|
|
|
71 |
|
|
|
|
|
71 |
|
|
|
Equity-settled share based payment awards |
|
|
|
2,035 |
|
|
|
|
|
2,035 |
|
|
|
Loss for
the period |
|
|
|
|
|
|
|
(19,477 |
) |
|
(19,477 |
) |
|
|
Other
comprehensive income |
|
|
|
|
|
(4,731 |
) |
|
|
|
(4,731 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2018 |
|
624 |
|
239,055 |
|
2,594 |
|
|
(202,144 |
) |
|
40,129 |
|
|
|
1 Issue of 3,341 shares
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024